PubRank

Harry R Büller

Author PubWeight™ 188.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012 11.86
2 Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013 7.76
3 Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 5.41
4 Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010 5.06
5 Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006 4.75
6 Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013 4.43
7 Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004 3.55
8 Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 2008 3.10
9 Bidirectional relation between inflammation and coagulation. Circulation 2004 3.00
10 Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003 2.86
11 The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol 2003 2.71
12 Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ 2012 2.38
13 Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med 2011 2.34
14 Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med 2003 2.33
15 The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 2003 2.33
16 The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005 2.31
17 Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med 2011 2.28
18 Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002 2.16
19 Direct thrombin inhibitors. N Engl J Med 2005 2.15
20 Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J 2012 2.08
21 Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ 2010 1.99
22 Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006 1.95
23 Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009 1.93
24 Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004 1.92
25 Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005 1.82
26 Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med 2002 1.81
27 Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011 1.63
28 Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013 1.58
29 Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2010 1.57
30 Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest 2013 1.55
31 Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost 2009 1.51
32 Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood 2013 1.51
33 Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010 1.50
34 Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003 1.49
35 Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. Ann Intern Med 2014 1.42
36 Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. Thromb Haemost 2012 1.40
37 Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002 1.32
38 A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005 1.20
39 Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol 2005 1.20
40 Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009 1.17
41 Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009 1.17
42 Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002 1.16
43 Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005 1.14
44 Embolus location affects the sensitivity of a rapid quantitative D-dimer assay in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med 2002 1.14
45 Cerebral white matter lesions predict both ischemic strokes and myocardial infarctions in patients with established atherosclerotic disease. Atherosclerosis 2005 1.14
46 Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002 1.13
47 The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Chest 2007 1.12
48 The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009 1.11
49 Simplification of the diagnostic management of suspected deep vein thrombosis. Arch Intern Med 2002 1.09
50 Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004 1.05
51 Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res 2010 1.04
52 Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012 1.04
53 Travel and the risk of symptomatic venous thromboembolism. Thromb Haemost 2003 1.03
54 Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008 1.01
55 Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost 2007 1.01
56 Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol 2006 1.00
57 A clinical prediction model for the presence of peripheral arterial disease--the benefit of screening individuals before initiation of measurement of the ankle-brachial index: an observational study. Vasc Med 2007 0.98
58 Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One 2012 0.96
59 Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood 2010 0.96
60 Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol 2010 0.96
61 Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients. Ann Fam Med 2010 0.95
62 Estimates of risk of venous thrombosis during pregnancy and puerperium are not influenced by diagnostic suspicion and referral basis. Am J Obstet Gynecol 2004 0.95
63 Secondary prophylaxis with warfarin for venous thromboembolism. N Engl J Med 2003 0.95
64 Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009 0.94
65 Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis. Intensive Care Med 2003 0.94
66 Symptomatic peripheral arterial disease: the value of a validated questionnaire and a clinical decision rule. Br J Gen Pract 2006 0.93
67 A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 2009 0.92
68 Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005 0.92
69 Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica 2005 0.91
70 Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004 0.91
71 Low incidence of deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study of 335 patients. Acta Orthop 2006 0.91
72 The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med 2007 0.91
73 Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010 0.89
74 Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015 0.89
75 Concerns in using multi-detector computed tomography for diagnosing pulmonary embolism in daily practice. A cross-sectional analysis using expert opinion as reference standard. Thromb Res 2012 0.88
76 Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003 0.88
77 Influenza infection and risk of acute pulmonary embolism. Thromb J 2007 0.87
78 Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004 0.85
79 Acute pulmonary embolism. Part 1: epidemiology and diagnosis. Nat Rev Cardiol 2010 0.85
80 Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. Thromb Haemost 2007 0.85
81 Dutch orthopedic thromboprophylaxis: a 5-year follow-up survey. Acta Orthop 2009 0.85
82 Ruling out clinically suspected pulmonary embolism by assessment of clinical probability and D-dimer levels: a management study. Thromb Haemost 2003 0.85
83 The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr 2002 0.84
84 Diagnostic strategy using a modified clinical decision rule and D-dimer test to rule out pulmonary embolism in elderly in- and outpatients. Thromb Haemost 2005 0.84
85 Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010 0.84
86 Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials. Thromb Haemost 2011 0.84
87 Applicability of the ankle-brachial-index measurement as screening device for high cardiovascular risk: an observational study. BMC Cardiovasc Disord 2012 0.84
88 The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007 0.83
89 Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study. Thromb Haemost 2007 0.83
90 Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002 0.83
91 Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost 2016 0.82
92 The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med 2002 0.82
93 Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO J 2006 0.82
94 Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002 0.82
95 Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 2009 0.82
96 Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 2004 0.82
97 Compliance of Dutch orthopedic departments with national guidelines on thromboprophylaxis. A survey of Dutch orthopedic thromboprohylaxis. Acta Orthop 2005 0.82
98 Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica 2009 0.82
99 Improving stroke prevention in patients with atrial fibrillation. Trials 2013 0.81
100 Optimisation of the diagnostic strategy for suspected deep-vein thrombosis in primary care. Thromb Haemost 2010 0.81
101 Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 2008 0.81
102 Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. Eur J Heart Fail 2010 0.81
103 The influence of pituitary, adrenal, and parathyroid hormones on hemostasis and thrombosis. Semin Thromb Hemost 2011 0.80
104 Hormones and cardiovascular disease: a shift in paradigm with clinical consequences? Semin Thromb Hemost 2009 0.80
105 Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004 0.80
106 Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study. Crit Care 2005 0.80
107 Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels. Thromb Res 2008 0.80
108 Deep vein thrombosis after arthroscopic anterior cruciate ligament reconstruction: a prospective cohort study of 100 patients. Arthroscopy 2013 0.79
109 Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis. Thromb Haemost 2003 0.79
110 Peripheral arterial disease: the gap between common practice and the Dutch College of General Practitioners guideline. Eur J Gen Pract 2004 0.78
111 Systolic heart failure: a prothrombotic state. Semin Thromb Hemost 2009 0.78
112 Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost 2010 0.78
113 Risk of thromboembolism and bleeding after general surgery in patients with atrial fibrillation. Am J Cardiol 2005 0.78
114 New anticoagulants: moving on from scientific results to clinical implementation. Ann Med 2011 0.77
115 Biomarkers in pulmonary embolism. Curr Opin Cardiol 2004 0.77
116 The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002 0.77
117 Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 2006 0.77
118 Recurrent deep venous thrombosis during optimal anticoagulation and overt hyperthyroidism: a case report. Blood Coagul Fibrinolysis 2007 0.77
119 Quantitative trait locus for protein C in a family with thrombophilia. Thromb Haemost 2010 0.77
120 Wells Rule and d-Dimer Testing to Rule Out Pulmonary Embolism: A Systematic Review and Individual-Patient Data Meta-analysis. Ann Intern Med 2016 0.77
121 Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study. BMJ Open 2011 0.77
122 Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med 2015 0.77
123 Levels of prolactin in relation to coagulation factors and risk of venous thrombosis. Results of a large population-based case-control study (MEGA-study). Thromb Haemost 2012 0.76
124 Clinically suspected acute recurrent pulmonary embolism: a diagnostic challenge. Thromb Haemost 2007 0.76
125 Comparison of 4- and 64-slice CT scanning in the diagnosis of pulmonary embolism. Thromb Haemost 2009 0.76
126 Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study. Blood Coagul Fibrinolysis 2005 0.76
127 Contra: "Antidotes for novel anticoagulants?"--Do we really need them. Thromb Haemost 2012 0.76
128 A rebuttal: Counseling pregnant women with factor V Leiden homozygosity: use absolute instead of relative risks. Thromb Haemost 2002 0.76
129 Unselected women with elevated levels of factor VIII:C or homocysteine are not at increased risk for obstetric complications. Thromb Haemost 2004 0.76
130 Chlamydial LPS antibodies, intima-media thickness and ischemic events in patients with established atherosclerosis. Atherosclerosis 2003 0.76
131 The risk of venous thrombosis after air travel: contribution of clinical risk factors. Br J Haematol 2014 0.76
132 The role of activated protein C in cancer progression. Thromb Res 2010 0.76
133 The performance of two rapid quantitative D-dimer assays in 287 patients with clinically suspected pulmonary embolism. Thromb Res 2002 0.76
134 Duration of warfarin in pulmonary embolism. Chest 2006 0.75
135 When do we need what evidence? J Clin Epidemiol 2003 0.75
136 Could D-dimer provide a definitive diagnosis in patients with suspected pulmonary embolism? Nat Clin Pract Cardiovasc Med 2006 0.75
137 Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003 0.75
138 Edoxaban versus warfarin for venous thromboembolism. N Engl J Med 2014 0.75
139 Excluding pulmonary embolism in primary care using the Wells-rule in combination with a point-of care D-dimer test: a scenario analysis. BMC Fam Pract 2010 0.75
140 The additional value of the CRP test in patients in whom the primary care physician excluded pulmonary embolism. Eur J Gen Pract 2013 0.75
141 Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 2015 0.75
142 Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost 2017 0.75
143 Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. Eur J Heart Fail 2010 0.75
144 Prolactin and venous thrombosis: indications for a novel risk factor? Arterioscler Thromb Vasc Biol 2010 0.75
145 Pulmonary embolism as a first clinical sign of occult malignancy: a prospective follow-up study. Thromb Haemost 2006 0.75
146 Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study. Thromb Res 2008 0.75
147 Heparin and survival in cancer patients. Hematol Oncol Clin North Am 2010 0.75
148 Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. Atherosclerosis 2002 0.75
149 Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J Am Coll Cardiol 2005 0.75
150 Comparison of the clinical usefulness of two quantitative D-Dimer tests in patients with a low clinical probability of pulmonary embolism. Thromb Res 2008 0.75
151 [Thromboprophylaxis in outpatients with cancer?]. Ned Tijdschr Geneeskd 2014 0.75
152 Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis. Pathophysiol Haemost Thromb 2004 0.75
153 Combined training of GPs and practice-assistants on peripheral arterial disease: positive effects after six months. Fam Pract 2005 0.75
154 High factor VIII plasma levels as a risk factor for venous thrombosis: no evidence of inheritance from a family cohort study. Haematologica 2004 0.75
155 Antithrombotic therapy and cancer. Curr Opin Hematol 2004 0.75
156 Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin. Haematologica 2003 0.75
157 The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol 2003 0.75
158 Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost 2017 0.75
159 Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia - a prospective family cohort study in asymptomatic subjects. Thromb Haemost 2009 0.75
160 Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Intern Emerg Med 2014 0.75
161 New anticoagulants and thromboprophylaxis. Br J Surg 2005 0.75
162 Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis. Thromb Haemost 2017 0.75
163 Risk of cardiovascular disease in double heterozygous carriers and homozygous carriers of F5 R506Q (factor V Leiden) and F2 (prothrombin) G20210A: a retrospective family cohort study. Br J Haematol 2011 0.75
164 Application of a decision rule and a D-dimer assay in the diagnosis of pulmonary embolism. Thromb Haemost 2010 0.75
165 Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost 2016 0.75
166 New developments in parenteral anticoagulation for arterial and venous thromboembolism. Best Pract Res Clin Haematol 2013 0.75
167 Hemostatic abnormalities and arterial thrombosis. Semin Thromb Hemost 2009 0.75
168 Benefit of selective factor inhibition. Semin Thromb Hemost 2002 0.75
169 Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost 2016 0.75
170 Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thromb Haemost 2017 0.75
171 Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med 2003 0.75